Papers
1
Total Citations
13
H-Index
1
About
Dr. Xianwen Shang is a pioneering oncologist whose research focuses on neoadjuvant immunotherapy for esophageal squamous cell carcinoma (ESCC). His most notable contribution is the Keystone-001 trial, a prospective phase II study evaluating pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable stage III ESCC. The interim analysis, published in 2021, demonstrated promising safety and efficacy, achieving 13 citations and establishing a new paradigm for preoperative immunotherapy in this challenging cancer. Dr. Shang’s work addresses a critical gap in esophageal cancer management, where standard neoadjuvant chemotherapy has limited success. By integrating immune checkpoint blockade with chemotherapy, his research offers potential for improved pathological complete response rates and long-term survival. His findings have influenced clinical trial design and sparked further investigation into combination strategies for ESCC. With a growing citation impact, Dr. Shang continues to advance the field of thoracic oncology, bridging immunotherapy and surgical oncology to improve outcomes for patients with locally advanced disease.
Research Focus
Key Achievements
Top Papers
- 1